Skip to content
Screener

Candel Therapeutics, Inc. CADL Q2 2026 earnings

Reported August 13, 2026 · Before market open

EPS-$0.52Miss by $0.28
EPS estimate-$0.24

Next report

Nov 12, 2026 (in 2 months)
EPS estimate-$0.30

Financials

Q2 2026

Income statement

See full
Operating income-$26.7M-139%
Net income-$38.9M-711%
EPS (diluted)-$0.52-478%

Balance sheet

See full
Cash & equivalents$201.6M+100%
Total debt$2.8M-66.8%
Total equity$126.1M+39.8%
Total assets$208.1M+96.4%

Cash flow

See full
Operating cash flow-$17.2M-93.3%
CapEx$69.0K+123%
Free cash flow-$17.3M-93.4%

Valuation & ratios

Valuation

as of 09/17/26
See full
Market cap$843.23M+217%
Enterprise value$644.44M+272%

Returns & leverage

See full
Return on equity-81.8%—
Debt / equity0×-0.1×
Current ratio16.1×+9.1×

FAQ

When did Candel Therapeutics, Inc. report Q2 2026 earnings?
Candel Therapeutics, Inc. (CADL) reported Q2 2026 earnings on August 13, 2026 before market open.
What were Candel Therapeutics, Inc.'s Q2 2026 revenue and EPS?
Candel Therapeutics, Inc. reported eps of $-0.52 for Q2 2026.
Did Candel Therapeutics, Inc. beat estimates in Q2 2026?
EPS missed the consensus estimate of $-0.24 by $0.28.
How did Candel Therapeutics, Inc.'s Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 477.8% from $-0.09.
Where can I find Candel Therapeutics, Inc.'s Q2 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-347957) and the 10-Q periodic report (0001193125-26-347980) directly on SEC EDGAR. The filing index links above go to sec.gov.